LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a virtual Analyst Event.
Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022
Five-target collaboration with Lilly highlights significant potential of ProQR’s Axiomer® RNA base-editing pla
… we are excited by the potential of our next-generation Axiomer RNA editing technology. In addition to using this … this trial in 2022. ProQR has been further optimizing the Axiomer ® Editing Oligonucleotide (EON) designs and will develop selected genetic eye disease targets with Axiomer ® . The Company anticipates providing further …
… pigmentosa ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across … pigmentosa. ProQR is accelerating the development of its Axiomer RNA editing platform and pipeline activities and … The Company will present further non-clinical data for Axiomer and announce its internal development targets in H2 …
ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022
Company plans to discuss findings from sepofarsen Illuminate trial w
Agreement provides ProQR with initial payment of €12.5M and up to €135M in further payments, as well as potential additional earn outs based on commercial sales in the US and EU
Divestment of sepofarsen and ultevursen supports ProQR’s strategic focus on the Axiomer®&
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas; initial pipeline targets to be disclosed in early 2023 with Analyst and Investor R&D event to be held in Q1 2023
Management Team appointments and p
… Board (SAB). In vivo proof of concept data for novel Axiomer ® RNA editing platform technology presented at the … 1/2 trial of QR-110, announcing the in vivo PoC for our Axiomer technology and the completion of the pre-clinical … programs and our novel RNA-editing technology, Axiomer ® . We are also thrilled with the spin out of Amylon …